Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Mallinckrodt
AstraZeneca
Harvard Business School
Merck

Last Updated: November 29, 2022

CLINICAL TRIALS PROFILE FOR SPRYCEL


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Sprycel

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00036738 ↗ Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, D Completed National Cancer Institute (NCI) Phase 2 2001-07-13 This phase II trial is studying how well fludarabine phosphate and total-body irradiation followed by donor peripheral blood stem cell transplant work in treating patients with acute lymphoblastic leukemia or chronic myelogenous leukemia that has responded to previous treatment with imatinib mesylate, dasatinib, or nilotinib. Giving low doses of chemotherapy, such as fludarabine phosphate, and total-body irradiation (TBI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving mycophenolate mofetil and cyclosporine after the transplant may stop this from happening.
NCT00036738 ↗ Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, D Completed Fred Hutchinson Cancer Research Center Phase 2 2001-07-13 This phase II trial is studying how well fludarabine phosphate and total-body irradiation followed by donor peripheral blood stem cell transplant work in treating patients with acute lymphoblastic leukemia or chronic myelogenous leukemia that has responded to previous treatment with imatinib mesylate, dasatinib, or nilotinib. Giving low doses of chemotherapy, such as fludarabine phosphate, and total-body irradiation (TBI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving mycophenolate mofetil and cyclosporine after the transplant may stop this from happening.
NCT00070499 ↗ Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia Active, not recruiting National Cancer Institute (NCI) Phase 2 2004-08-15 This randomized phase IIB trial studies imatinib mesylate at two different doses and dasatinib to see how well they work in treating patients with previously untreated chronic phase chronic myelogenous leukemia. Imatinib mesylate or dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT00099606 ↗ Phase I (PH I) Mad Refractory Solid Tumor Study Completed Bristol-Myers Squibb Phase 1 2004-07-01 The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, effect of food, and continue exploratory research of BMS-354825 in patients with solid tumors not responding to standard treatment, or for which no effective standard treatment exists.
NCT00101595 ↗ Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Completed Bristol-Myers Squibb Phase 2 2005-01-01 The purpose of this clinical research study is to learn if BMS-354825 will have activity as defined by hematologic responses in subjects with lymphoid blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia with primary or acquired resistance to imatinib mesylate.
NCT00101647 ↗ Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia Completed Bristol-Myers Squibb Phase 2 2004-12-01 The purpose of this clinical research study is to learn if BMS-354825 will have activity, defined by hematologic response, in subjects who have accelerated phase chronic myeloid leukemia (CML) who are resistant to or intolerant to imatinib mesylate. The safety of this treatment will also be studied.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sprycel

Condition Name

Condition Name for Sprycel
Intervention Trials
Leukemia 12
Chronic Myeloid Leukemia 10
Breast Cancer 9
Acute Lymphoblastic Leukemia 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sprycel
Intervention Trials
Leukemia 79
Leukemia, Myeloid 53
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 50
Leukemia, Lymphoid 33
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sprycel

Trials by Country

Trials by Country for Sprycel
Location Trials
United States 984
Canada 74
United Kingdom 59
Australia 43
Japan 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sprycel
Location Trials
Texas 66
California 46
Illinois 39
New York 38
Pennsylvania 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sprycel

Clinical Trial Phase

Clinical Trial Phase for Sprycel
Clinical Trial Phase Trials
Phase 4 4
Phase 3 10
Phase 2/Phase 3 1
[disabled in preview] 153
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sprycel
Clinical Trial Phase Trials
Completed 81
Terminated 31
Active, not recruiting 20
[disabled in preview] 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sprycel

Sponsor Name

Sponsor Name for Sprycel
Sponsor Trials
Bristol-Myers Squibb 74
National Cancer Institute (NCI) 56
M.D. Anderson Cancer Center 24
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sprycel
Sponsor Trials
Other 148
Industry 106
NIH 57
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Baxter
Johnson and Johnson
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.